The ‘Hynanodend Baltic Sea Network’ research project, which is being carried out in collaboration with universities in Germany, Poland, the United Kingdom, Sweden, Finland, Italy, France and the Netherlands, has got off to a successful start.
The “Hynanodend Baltic Sea Network” project is an international and interdisciplinary research project aimed at investigating new biomedical materials. As part of the ‘Functional Nanomaterials’ conference, experts from various European universities met on the Kleve campus under the patronage of Prof. Dr Amir Fahmi, Professor of Materials Science at Rhine-Waal University of Applied Sciences. The aim of this collaborative research is to develop new biomedical materials that can contribute to the diagnosis and treatment of various diseases, such as cancer or Alzheimer’s.
During an intensive exchange, the experts shared information on current research findings and the prospects for future developments in biomedical materials that can contribute to personalised medicine – a tailor-made treatment strategy for targeted therapy without side effects – and discussed innovative applications in the field of nanomedicine. Participants included representatives from Rhine-Waal University of Applied Sciences, the University of Siegen, the Universities of Łódź and Kraków in Poland, the University of Exeter in the UK, the KTH Royal Institute of Technology in Sweden, the Universities of Oulu in Finland and Tartu in Estonia, Radboud University in Nijmegen, the University of Naples in Italy, and the University of Tours in France.
The focus was in particular on the selective destruction of tumour cells or the selective destruction of beta-amyloid protein nanostructures. The beta-amyloid protein is essential for the transmission of information in our brain. If too many proteins are produced or if they accumulate to an excessive extent, this can disrupt the flow of information in the brain. The selective destruction of beta-amyloid proteins is intended to slow down the progression of symptoms and delay the onset of Alzheimer’s disease. The researchers involved planned new joint projects and emphasised their interest in further intensive collaboration to develop the next generation of hybrid nanomaterials for biomedical applications.
